CMS Finalizes GLOBE Model for Mandatory Medicare Part B Drug Pricing
CMS published a final rule on September 30, 2026 establishing the mandatory GLOBE Model, a most-favored-nation benchmark for Medicare Part B drug payment, with direct pricing and reimbursement consequences for drugmakers, payors and PBMs.
On September 30, 2026, the Centers for Medicare & Medicaid Services published a final rule establishing the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory Medicare Part B drug payment framework described as implementing a most-favored-nation approach to U.S. drug pricing. Unlike prior voluntary demonstration models, a mandatory model reaches all participating manufacturers and creates a direct link between U.S. reimbursement and prices a manufacturer offers in certain reference markets.
Why sophisticated counsel should care: mandatory MFN-style pricing changes the regulatory character of the initiative from pilot program to baseline reimbursement methodology, touching pricing agreements, Medicaid and commercial contracting strategy, PBM economics, and rebate and discount modeling. Health-system and provider-side buyers also face downstream effects on 340B and Part B supply economics, and the rule's reference-market definitions will likely generate statutory authority and procedural challenges under the Medicare program and the Administrative Procedure Act.
Concrete action: manufacturers, payors, PBMs and their counsel should read the final rule against current pricing and distribution contracts, assess implementation timetables and data-reporting obligations, and calendar any anticipated federal court challenge. Coverage here rests on a single firm alert; benchmark countries, price adjustment mechanics and compliance deadlines should be confirmed against the rule text before client advice.